Mandy Jackson

Partnering to Accelerate Clinical Breakthroughs: Fireside Chat with Penny Heaton, MD and Nauman Shah [Lunch in Room]

I’m heading to Boston for #BIO2025 with a packed schedule. At a Tuesday Super Session, I’m moderating a fireside chat with Johnson & Johnson’s Penny Heaton, global head, office of the chief medical officer, and Nauman Shah, global head of business development. convention.bio.org/program-1/pa...

Glad to hear it Ron! Take it easy!

Is this the mashup everyone who attends conferences in San Diego has been waiting? Comic-Con meets #ASH24

News Details

Also at #ASH24, Novo is presenting Phase II for once-daily PKR activator etavipovat in sickle cell disease from the Phase II/III HIBISCUS trial. It reduced VOCs by half, improved hemoglobin and hemolysis. Phase III data due in 2026. Curtain raiser press release: www.novonordisk.com/content/nnco...

$BEAM In 7 patients treated still no VOCs post engraftment in PhaseI/II trial of BEAM-101 base editor for sickle cell disease. Beam Therapeutics will present Preclinical data tomorrow for next-gen base editing program in SCD that uses proprietary antibody for conditioning instead of busulfan. #ASH24

$BIOA Down 74% after hours on news that BioAge is ending the Phase II trial of its muscle atrophy drug in combination with Lilly’s weight loss drug Zepbound due to liver transaminitis. Two months after closing $238m IPO. ir.bioagelabs.com/news-release...

Happy Thanksgiving! 🦃🍗🥧

Amgen’s Phase II MariTide Data Lack Clarity Market Hoped For Much anticipated Phase II results in obesity for Amgen’s GLP-1 agonist/GIP antagonist showed up to 20% weight loss, but without detailed data the drug’s competitiveness is hard to ascertain.

Lots of questions still to be answered whenever we get to see more data from Amgen’s Phase II study of MariTide in obesity. For now, we’ve got this frustrating initial disclosure of partial and pooled data. $AMGN insights.citeline.com/scrip/r-and-...

Restoring hippocampal glucose metabolism rescues cognition across Alzheimer’s disease pathologies Impaired cerebral glucose metabolism is a pathologic feature of Alzheimer’s disease (AD), with recent proteomic studies highlighting disrupted glial metabolism in AD. We report that inhibition of indo...

Exciting new discovery from colleagues @stanfordmedicine.bsky.social, astrocyte metabolism compromised by amyloid and tau oligomers leading to insufficient support for neurons. Possible new target for treating AD.

www.science.org/doi/10.1126/...

My track record over here on Bluesky isn’t great, but I aim to improve. Since my last post was about my trip to Idyllwild, here are photos from my 25th wedding anniversary trip last month in Sedona, a much needed break. 🏜️ I’ll be at ASH here in San Diego in December and at JPM in SF in January.

Spending a long weekend in Idyllwild. Going to be staring at this view while I cook chili and watch Super Bowl commercials. 🏔️❄️🌲

JPM24 Day 4 coverage from Scrip, free to read here: scrip.citeline.com/SC149618/JP-...

Here’s our JPM24 day 3 coverage, free to read without a subscription. We’ll have a day 4 notebook tomorrow and several more stories in the coming days and weeks based on interviews in San Francisco this week. Stay tuned! scrip.citeline.com/SC149610/JP-...

scrip.citeline.com/SC149592/JP-...

Free to read without a subscription, Scrip’s J.P. Morgan Healthcare Conference day 1 and 2 coverage. More to come in the coming days. scrip.citeline.com/SC149603/JP-...

$BLUE gene therapy and $VRTX/ $CRSP gene-editing therapy for sickle cell disease both approved in the US. Looking forward to data updates and conversations at #ASH2023 www.fda.gov/news-events/...

$ABBV to Acquire $CERE Cerevel Therapeutics in Transformative Transaction to Strengthen Neuroscience Pipeline - $8.7bn deal; conference call tomorrow morning www.prnewswire.com/news-release...

Hi, friends. Made it over here just in time for #ASH23 and #JPM24. Hoping for a better experience than that other alternative to X. Bear with me. 😬😀